Topics
KS.Currency
CsA-free therapy, whereas 9.2 % of those receiving SRLCsA (P0.03) developed tumors. In conclusion, in the present report, both patients showed KS regression without an increased risk of acute rejection, which is the main problem with classical management of posttransplantation KS. SRL offers a new and promising approach to the management of posttransplantation KS and probably to other types of malignancies in organ transplant recipients. The immunosuppressive efficacy and antitumor activity of SRL confers a unique value to this drug in the long-term management of these patients
Between August 1966 and December 1989, 989 renal transplant recipients were followed up at the Renal...
Sirolimus (SRL) is an mTOR inhibitor that has been shown, in contrast to calcineurin inhibitors (CNI...
background Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
WOS: 000264891700020PubMed ID: 18452496SRL is a new and potent immunosuppressive agent that has been...
Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based o...
<p>Kaposi᾽s sarcoma (KS) can develop in 0.06% to 4.1% of kidney transplant recipients. Here we descr...
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immun...
© 2006 American Society of NephrologySirolimus (SRL) is a mammalian target of rapamycin inhibitor th...
Background. The aim of this study was to investigate retrospectively the clinical presentation, the ...
The incidence of Kaposi’s sarcoma (KS) among the recipients of solid organ transplants is about 500...
A case of observation of a patient who developed Kaposi’s sarcoma after kidney transplantation is pr...
Background. Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recip...
A case of a long-term management of a patient with Kaposi’s sarcoma developed as presumably related ...
Background. Renal transplant recipients have an increased cancer risk. The mammalian target of rapam...
Between August 1966 and December 1989, 989 renal transplant recipients were followed up at the Renal...
Sirolimus (SRL) is an mTOR inhibitor that has been shown, in contrast to calcineurin inhibitors (CNI...
background Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
WOS: 000264891700020PubMed ID: 18452496SRL is a new and potent immunosuppressive agent that has been...
Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based o...
<p>Kaposi᾽s sarcoma (KS) can develop in 0.06% to 4.1% of kidney transplant recipients. Here we descr...
Renal transplant recipients are susceptible to Kaposi's sarcoma (KS) because of treatment with immun...
© 2006 American Society of NephrologySirolimus (SRL) is a mammalian target of rapamycin inhibitor th...
Background. The aim of this study was to investigate retrospectively the clinical presentation, the ...
The incidence of Kaposi’s sarcoma (KS) among the recipients of solid organ transplants is about 500...
A case of observation of a patient who developed Kaposi’s sarcoma after kidney transplantation is pr...
Background. Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
Immunosuppressive treatment increases the risk of infection and malignancy in organ transplant recip...
A case of a long-term management of a patient with Kaposi’s sarcoma developed as presumably related ...
Background. Renal transplant recipients have an increased cancer risk. The mammalian target of rapam...
Between August 1966 and December 1989, 989 renal transplant recipients were followed up at the Renal...
Sirolimus (SRL) is an mTOR inhibitor that has been shown, in contrast to calcineurin inhibitors (CNI...
background Recipients of organ transplants are susceptible to Kaposi’s sarcoma as a result of treat...
Add to ORKG